Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

Six digital platforms supporting at home cardiac rehab given conditional recommendations People with heart disease will be able to do their recovery sessions from home rather than travelling for ...

Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

Capacity impact Switching from comparator treatment options to durvalumab with tremelimumab may have capacity implications. Transitioning from atezolizumab with bevacizumab is expected to save 1 ...

Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults. Last reviewed: 19 August 2025 Next review: ...

3 Committee discussion The evaluation committee considered evidence submitted by AstraZeneca, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See ...

Durvalumab (Imfinzi) with tremelimumab (Imjudo) is available on the NHS. It is a possible treatment for advanced or unresectable (cannot be surgically removed) hepatocellular carcinoma (liver cancer) ...

Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults ...

Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults. Durvalumab with tremelimumab ...